Inhaltsbereich
| 120 Einträge | 1, 2, 3, 4, 5, 6 › » |
Seite 1 / 6
 Druckansicht
|
| Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. |
| Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF |
| Lancet (London, England). 2015 May 31. pii: S0140-6736(15)60995-3. doi: 10.1016/S0140-6736(15)60995-3 |
| PMID: 26040499 |
| Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. |
| Foukakis T, von Minckwitz G, Bengtsson NO, Brandberg Y, Wallberg B, Fornander T, Mlineritsch B, Schmatloch S, Singer CF, Steger G, Egle D, Karlsson E, Carlsson L, Loibl S, Untch M, Hellström M, Johansson H, Anderson H, Malmström P, Gnant M, Greil R, Möbus V, Bergh J |
| JAMA. 2016 Nov 8. pii: 2579866. doi: 10.1001/jama.2016.15865 |
| PMID: 27825007 |
| Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. |
| Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A, Rudas M, Moinfar F, Gruber C, Petru E, Bartsch R, Tendl KA, Fuchs D, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits M, Gnant M |
| Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Jan 31. pii: 1078-0432.CCR-16-2373. doi: 10.1158/1078-0432.CCR-16-2373 |
| PMID: 28143867 |
| 262PDDOCETAXEL + TRASTUZUMAB +/- NON-PEGYLATED LIPOSOMAL DOXORUBICIN +/- BEVACIZUMAB IN THE NEOADJUVANT TREATMENT OF EARLY, HER2-POSITIVE BREAST CANCER: FIRST RESULTS OF ABCSG-32. |
| Steger GG, Greil R, Hubalek M, Fridrik MA, Singer C, Bartsch R, Balic M, Dubsky P, Egle D, Gampenrieder SP, Pfeiler G, Mayr D, Czech T, Rinnerthaler G, Petzer AL, Sevelda P, Lang A, Frantal S, Rudas M, Gnant M |
| Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Feb 7. pii: 2240998. doi: 10.1093/annonc/mdu327.10 |
| PMID: 28172028 |
| Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centres. |
| van Dam PA, Tomatis M, Marotti L, Heil J, Mansel RE, Rosselli Del Turco M, van Dam PJ, Casella D, Bassani LG, Danei M, Denk A, Egle D, Emons G, Friedrichs K, Harbeck N, Kiechle M, Kimmig R, Koehler U, Kuemmel S, Maass N, Mayr C, Prové A, Rageth C, Regolo L, Lorenz-Salehi F, Sarlos D, Singer C, Sohn C, Staelens G, Tinterri C, Audisio R, Ponti A |
| European journal of cancer (Oxford, England : 1990). 2017 Sep 4. pii: S0959-8049(17)31160-7. doi: 10.1016/j.ejca.2017.07.040 |
| PMID: 28881247 |
| Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial). |
| Rinnerthaler G, Gampenrieder SP, Petzer A, Burgstaller S, Fuchs D, Rossmann D, Balic M, Egle D, Rumpold H, Singer CF, Bartsch R, Petru E, Melchardt T, Ulmer H, Mlineritsch B, Greil R |
| BMC cancer. 2018 Nov 6. doi: 10.1186/s12885-018-4979-0. pii: 10.1186/s12885-018-4979-0 |
| PMID: 30400780 |
| A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). |
| Mayer IA, Prat A, Egle D, Blau S, Perez Fidalgo JA, Gnant M, Fasching PA, Colleoni M, Wolff AC, Winer EP, Singer CF, Hurvitz SA, Garcia Estevez L, van Dam PA, Kümmel S, Mundhenke C, Holmes FA, Babbar N, Charbonnier L, Diaz-Padilla I, Vogl FD, Sellami D, Arteaga CL |
| Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Feb 5. pii: 1078-0432.CCR-18-3160. doi: 10.1158/1078-0432.CCR-18-3160 |
| PMID: 30723140 |
| Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. |
| Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Jakesz R, Marth C, Sevelda P, Mlineritsch B, Exner R, Fesl C, Frantal S, Singer CF |
| The Lancet. Oncology. 2019 Feb 19. pii: S1470-2045(18)30862-3. doi: 10.1016/S1470-2045(18)30862-3 |
| PMID: 30795951 |
| Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. |
| Steger GG, Egle D, Bartsch R, Pfeiler G, Petru E, Greil R, Helfgott R, Marth C, Öhler L, Hubalek M, Lang A, Tinchon C, Haslbauer F, Redl A, Hock K, Hennebelle M, Mraz B, Gnant M |
| Breast (Edinburgh, Scotland). 2020 Jan 31. pii: S0960-9776(20)30036-9. doi: 10.1016/j.breast.2020.01.035 |
| PMID: 32062536 |
| Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). |
| Singer CF, Pfeiler G, Hubalek M, Bartsch R, Stöger H, Pichler A, Petru E, Bjelic-Radisic V, Greil R, Rudas M, Maria Tea MK, Wette V, Petzer AL, Sevelda P, Egle D, Dubsky PC, Filipits M, Fitzal F, Exner R, Jakesz R, Balic M, Tinchon C, Bago-Horvath Z, Frantal S, Gnant M |
| European journal of cancer (Oxford, England : 1990). 2020 Apr 20. pii: S0959-8049(20)30159-3. doi: 10.1016/j.ejca.2020.03.018 |
| PMID: 32325419 |
| Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial. |
| Bjelic-Radisic V, Fitzal F, Knauer M, Steger G, Egle D, Greil R, Schrenk P, Balic M, Singer C, Exner R, Soelkner L, Gnant M |
| BMC cancer. 2020 May 6. doi: 10.1186/s12885-020-06894-2. pii: 10.1186/s12885-020-06894-2 |
| PMID: 32375735 |
| The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. |
| Dubsky PC, Singer CF, Egle D, Wette V, Petru E, Balic M, Pichler A, Greil R, Petzer AL, Bago-Horvath Z, Fesl C, Meek SM, Kronenwett R, Rudas M, Gnant M, Filipits M |
| European journal of cancer (Oxford, England : 1990). 2020 Jun 2. pii: S0959-8049(20)30223-9. doi: 10.1016/j.ejca.2020.04.020 |
| PMID: 32502940 |
| A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort. |
| Dubsky P, Van't Veer L, Gnant M, Rudas M, Bago-Horvath Z, Greil R, Lujinovic E, Buresch J, Rinnerthaler G, Hulla W, Moinfar F, Egle D, Herz W, Dreezen C, Frantal S, Filipits M |
| ESMO open. 2020 Dec 31. pii: S2059-7029(20)32868-4. doi: 10.1016/j.esmoop.2020.100006 |
| PMID: 33399073 |
| Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. |
| Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant M |
| The Lancet. Oncology. 2021 Jan 15. pii: S1470-2045(20)30642-2. doi: 10.1016/S1470-2045(20)30642-2 |
| PMID: 33460574 |
| Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34. |
| Bartsch R, Singer CF, Pfeiler G, Hubalek M, Stoeger H, Pichler A, Petru E, Bjelic-Radisic V, Greil R, Rudas M, Muy-Kheng TM, Wette V, Petzer AL, Sevelda P, Egle D, Dubsky PC, Filipits M, Fitzal F, Exner R, Jakesz R, Balic M, Tinchon C, Bago-Horvath Z, Frantal S, Gnant M |
| British journal of cancer. 2021 Mar 24. doi: 10.1038/s41416-021-01284-2. pii: 10.1038/s41416-021-01284-2 |
| PMID: 33762716 |
| Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. |
| Gnant M, Fitzal F, Rinnerthaler G, Steger GG, Greil-Ressler S, Balic M, Heck D, Jakesz R, Thaler J, Egle D, Manfreda D, Bjelic-Radisic V, Wieder U, Singer CF, Melbinger-Zeinitzer E, Haslbauer F, Sevelda P, Trapl H, Wette V, Wimmer K, Gampenrieder SP, Bartsch R, Kacerovsky-Strobl S, Suppan C, Brunner C, Deutschmann C, Soelkner L, Fesl C, Greil R |
| The New England journal of medicine. doi: 10.1056/NEJMoa2104162 |
| PMID: 34320285 |
| The OncoMasTR test predicts distant recurrence in estrogen receptor-positive, HER2-negative early-stage breast cancer: A validation study in ABCSG Trial 8. |
| Filipits M, Rudas M, Kainz V, Singer CF, Fitzal F, Bago-Horvath Z, Greil R, Balic M, Regitnig P, Halper S, Hulla W, Egle D, Barron S, Loughman T, O'Leary D, Gallagher WM, Hlauschek D, Gnant M, Dubsky P |
| Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Aug 11. pii: 1078-0432.CCR-21-1023. doi: 10.1158/1078-0432.CCR-21-1023 |
| PMID: 34380638 |
| Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). |
| Weber WP, Matrai Z, Hayoz S, Tausch C, Henke G, Zwahlen DR, Gruber G, Zimmermann F, Seiler S, Maddox C, Ruhstaller T, Muenst S, Ackerknecht M, Kuemmel S, Bjelic-Radisic V, Kurzeder C, Újhelyi M, Vrieling C, Satler R, Meyer I, Becciolini C, Bucher S, Simonson C, Fehr PM, Gabriel N, Maráz R, Sarlos D, Dedes KJ, Leo C, Berclaz G, Dubsky P, Exner R, Fansa H, Hager C, Reisenberger K, Singer CF, Reitsamer R, Reinisch M, Winkler J, Lam GT, Fehr MK, Naydina T, Kohlik M, Clerc K, Ostapenko V, Fitzal F, Nussbaumer R, Maggi N, Schulz A, Markellou P, Lelièvre L, Egle D, Heil J, Knauer M |
| Breast (Edinburgh, Scotland). 2021 Sep 8. pii: S0960-9776(21)00458-6. doi: 10.1016/j.breast.2021.09.004 |
| PMID: 34555676 |
| Persistence of ctDNA in breast cancer patients during neoadjuvant treatment is a significant predictor of poor tumour response. |
| Zhou Q, Gampenrieder SP, Frantal S, Rinnerthaler G, Singer CF, Egle D, Pfeiler G, Bartsch R, Wette V, Pichler A, Petru E, Dubsky PC, Bago-Horvath Z, Fesl C, Rudas M, Ståhlberg A, Graf R, Weber S, Dandachi N, Filipits M, Gnant M, Balic M, Heitzer E |
| Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Dec 3. pii: 1078-0432.CCR-21-3231. doi: 10.1158/1078-0432.CCR-21-3231 |
| PMID: 34862246 |
| Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry. |
| Gampenrieder SP, Rinnerthaler G, Tinchon C, Petzer A, Balic M, Heibl S, Schmitt C, Zabernigg AF, Egle D, Sandholzer M, Singer CF, Roitner F, Hager C, Andel J, Hubalek M, Knauer M, Greil R |
| Breast cancer research : BCR. 2021 Dec 14. doi: 10.1186/s13058-021-01492-x. pii: 10.1186/s13058-021-01492-x |
| PMID: 34906198 |
| 120 Einträge | 1, 2, 3, 4, 5, 6 › » |
Seite 1 / 6
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
